“…The limitations of smallmolecule chemotherapeutic drugs, such as insufficient water solubility, low bioavailability, and toxic effects on normal tissues, lead to drug resistance, poor efficacy, metastasis, and undesirable side effects. [1] Various nanoplatforms have been developed for efficient drug delivery to the tumor site to enhance its therapeutic efficacy and reduce its toxic side effects including inorganic nanosystems, [2] metal-phenolic networks, [3] micelles, [4] liposomes, [5] dendrimers, [6] and nanogels. [7] However, few nanoplatforms are available for clinical investigation mainly due to the defects including poor drug loading efficacy, potential systematic toxicity and immunogenicity, multi-step synthetic processes, and complex components and structure.…”